Assetmark Inc. Has $372,000 Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Assetmark Inc. increased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 457.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,544 shares of the company’s stock after purchasing an additional 3,729 shares during the period. Assetmark Inc.’s holdings in HealthEquity were worth $372,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. International Assets Investment Management LLC bought a new position in HealthEquity in the 2nd quarter valued at about $35,000. Paladin Wealth LLC acquired a new stake in shares of HealthEquity during the 3rd quarter worth approximately $39,000. GAMMA Investing LLC increased its stake in HealthEquity by 114.8% in the second quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock valued at $51,000 after acquiring an additional 318 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in HealthEquity during the second quarter valued at approximately $73,000. Finally, 1620 Investment Advisors Inc. bought a new stake in HealthEquity during the third quarter worth $112,000. Institutional investors and hedge funds own 99.55% of the company’s stock.

Insider Transactions at HealthEquity

In related news, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now owns 54,719 shares in the company, valued at $4,540,582.62. The trade was a 13.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Frank Corvino sold 1,039 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total value of $99,847.90. Following the sale, the director now owns 3,784 shares of the company’s stock, valued at approximately $363,642.40. The trade was a 21.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,536 shares of company stock worth $884,517 over the last ninety days. 2.20% of the stock is owned by insiders.

HealthEquity Price Performance

HQY stock opened at $98.98 on Friday. The company has a market capitalization of $8.64 billion, a P/E ratio of 82.48, a PEG ratio of 1.48 and a beta of 0.52. The company has a fifty day moving average price of $85.02 and a 200-day moving average price of $81.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $101.17.

HealthEquity (NASDAQ:HQY) last announced its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.16. The business had revenue of $299.93 million during the quarter, compared to analyst estimates of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. As a group, equities analysts expect that HealthEquity, Inc. will post 2.27 EPS for the current year.

Wall Street Analysts Forecast Growth

HQY has been the topic of several recent analyst reports. The Goldman Sachs Group started coverage on HealthEquity in a research note on Friday. They issued a “neutral” rating and a $108.00 price target on the stock. BTIG Research boosted their target price on HealthEquity from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Thursday. Bank of America increased their target price on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft lifted their price target on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Finally, JMP Securities reissued a “market outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research note on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $107.23.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.